Patent Baristas

I will be attending the American Conference Institute’s 7th Advanced Forum on Biotech Patents: Analysis, Insights and Strategies for New Challenges in Biotech Patent Practices in Boston, MA on November 29 and 30. I will be on a panel discussion moderated by Dennis Crouch, entitled “Roundtable Wrap Up – Reviewing the Year in Patents with […]

A new blog I came across recently is the Daily Dose of IP, a blog by Mark Reichel that is a source of daily tidbits on IP law. Daily Dose of IP (or DDIP for short), focuses on a variety of issues including patents, trademarks, copyrights and trade secrets and provides information on IP issues […]

The U.S. Court of Appeals for the Federal Circuit again hammers home the message that you can’t make a silk purse from a sow’s ear – or, at the very least, you can’t turn a known compound into an unknown (novel and, therefore, patentable) compound. In Abbott Laboratories v. Baxter Pharmaceutical Products (Fed. Cir. 06-1021, […]

Robert Ambrogi’s LawSites is running a LawSites Poll: Your Top Legal Blog. Deemed “an experiment”, Robert hopes to use the poll to deal with the flood of law blogs. Robert wants to know: What is the one law-related blog you feel you must read as regularly as possible? No fair naming your own. From your […]

Many are asking what will happen if Democrats take control of the House and Senate. While I’m not interested in taking sides, I think that the issue is certainly on everyone’s mind at the moment since it could effect how business is done after the elections. In the end, I think that the issues will […]

In Go Medical v. Inmed Corp, the Federal Circuit reviewed the decision of the US District Court for the Northern District of Georgia concerning patent invalidity, trademark infringement and damages awards related to licensing of a patented catheter. The urinary catheter had been licensed to Medical Marketing Group (MMG) by Go Medical. The Federal Circuit, […]

India’s leading Para IV challenger – Dr. Reddy’s Laboratories (DRL) has finally zeroed down to settle its pending Para IV patent litigation with GlaxoSmithKline (GSK) over the blockbuster anti-migraine drug, Imitrex, generically known as Sumatriptan Succinate which is worth around US $ 890 million in sales in the U.S. market. GSK, under the terms of […]

After a jury determined that Stratagene infringed on Invitrogen’s U.S. Patent No. 4,981,797 by making and selling its competent E. coli cell products (see earlier note), the court has now entered judgment awarding Invitrogen $16.2 million plus prejudgment interest, as well as reasonable attorney fees to be determined by the court. The judgment included a […]